PMID- 27067625
OWN - NLM
STAT- MEDLINE
DCOM- 20171106
LR  - 20220410
IS  - 2215-0374 (Electronic)
IS  - 2215-0366 (Linking)
VI  - 3
IP  - 5
DP  - 2016 May
TI  - Novel psychopharmacological therapies for psychiatric disorders: psilocybin and 
      MDMA.
PG  - 481-8
LID - S2215-0366(15)00576-3 [pii]
LID - 10.1016/S2215-0366(15)00576-3 [doi]
AB  - 4-phosphorloxy-N,N-dimethyltryptamine (psilocybin) and 
      methylenedioxymethamfetamine (MDMA), best known for their illegal use as 
      psychedelic drugs, are showing promise as therapeutics in a resurgence of 
      clinical research during the past 10 years. Psilocybin is being tested for 
      alcoholism, smoking cessation, and in patients with advanced cancer with anxiety. 
      MDMA is showing encouraging results as a treatment for refractory post-traumatic 
      stress disorder, social anxiety in autistic adults, and anxiety associated with a 
      life-threatening illness. Both drugs are studied as adjuncts or catalysts to 
      psychotherapy, rather than as stand-alone drug treatments. This model of 
      drug-assisted psychotherapy is a possible alternative to existing pharmacological 
      and psychological treatments in psychiatry. Further research is needed to fully 
      assess the potential of these compounds in the management of these common 
      disorders that are difficult to treat with existing methods.
CI  - Copyright (c) 2016 Elsevier Ltd. All rights reserved.
FAU - Mithoefer, Michael C
AU  - Mithoefer MC
AD  - Department of Psychiatry and Behavioral Sciences, Medical University of South 
      Carolina, Charleston, SC, USA. Electronic address: mmithoefer@mac.com.
FAU - Grob, Charles S
AU  - Grob CS
AD  - Department of Psychiatry, Harbor-UCLA Medical Center/Los Angeles BioMedical 
      Research Institute, Torrance, CA, USA.
FAU - Brewerton, Timothy D
AU  - Brewerton TD
AD  - Department of Psychiatry and Behavioral Sciences, Medical University of South 
      Carolina, Charleston, SC, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160405
PL  - England
TA  - Lancet Psychiatry
JT  - The lancet. Psychiatry
JID - 101638123
RN  - 0 (Psychotropic Drugs)
RN  - 2RV7212BP0 (Psilocybin)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Humans
MH  - Mental Disorders/*drug therapy
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*therapeutic use
MH  - Psilocybin/*therapeutic use
MH  - Psychopharmacology
MH  - Psychotropic Drugs/*therapeutic use
MH  - Randomized Controlled Trials as Topic
EDAT- 2016/04/14 06:00
MHDA- 2017/11/07 06:00
CRDT- 2016/04/13 06:00
PHST- 2015/10/20 00:00 [received]
PHST- 2015/12/16 00:00 [revised]
PHST- 2015/12/16 00:00 [accepted]
PHST- 2016/04/13 06:00 [entrez]
PHST- 2016/04/14 06:00 [pubmed]
PHST- 2017/11/07 06:00 [medline]
AID - S2215-0366(15)00576-3 [pii]
AID - 10.1016/S2215-0366(15)00576-3 [doi]
PST - ppublish
SO  - Lancet Psychiatry. 2016 May;3(5):481-8. doi: 10.1016/S2215-0366(15)00576-3. Epub 
      2016 Apr 5.